Mirum Pharmaceuticals Inc’s recent filing unveils that its SVP, GLOBAL CONTROLLER Howe Jolanda unloaded Company’s shares for reported $27213.0 on Jul 02 ’25. In the deal valued at $48.25 per share,564 shares were sold. As a result of this transaction, Howe Jolanda now holds 2,903 shares worth roughly $0.15 million.
Then, Howe Jolanda sold 477 shares, generating $23,411 in total proceeds. Upon selling the shares at $49.08, the SVP, GLOBAL CONTROLLER now owns 2,426 shares.
Before that, JOLANDA MARIE HOWE bought 477 shares. Mirum Pharmaceuticals Inc shares valued at $23,411 were divested by the Officer at a price of $49.08 per share.
A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering MIRM and reiterated its “Buy” recommendation on December 18, 2023.
Price Performance Review of MIRM
On Monday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock jump 1.18% to $53.28. Over the last five days, the stock has gained 5.57%. Mirum Pharmaceuticals Inc shares have risen nearly 48.33% since the year began. Nevertheless, the stocks have risen 28.85% over the past one year. While a 52-week high of $54.23 was reached on 07/14/25, a 52-week low of $36.20 was recorded on 04/09/25.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 52.29, which if violated will result in even more drops to 51.31. On the upside, there is a resistance level at 54.52. A further resistance level may holdings at 55.77.
How much short interest is there in Mirum Pharmaceuticals Inc?
A steep rise in short interest was recorded in Mirum Pharmaceuticals Inc stocks on 2025-06-13, dropping by 68863.0 shares to a total of 6.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.29 million shares. There was a decline of -1.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 13, 2023 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
